SCHEMBL30869683

SCHEMBL30869683

c1cc2c(cc1-c1cnc3[nH]ncc3c1)Oc1cc(-c3cnc4[nH]ncc4c3)ccc1N2CCN1C[C@H]2C[C@@H]1CO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.42
DYRK1A Q13627 5/20 0.42
WNT1 P04628 4/20 0.42
NAMPT P43490 1/20 0.40
CHRNA7 P36544 2/20 0.36
KCNH2 Q12809 2/20 0.36
MCHR1 Q99705 1/20 0.36
TNIK Q9UKE5 2/20 0.35
PIK3C3 Q8NEB9 2/20 0.34
SYK P43405 2/20 0.34
PDE10A Q9Y233 1/20 0.34
ABL1 P00519 2/20 0.33
MAP3K12 Q12852 1/20 0.33
BRAF P15056 1/20 0.33
AKT1 P31749 1/20 0.32
PIK3CA P42336 1/20 0.32
JAK2 O60674 2/20 0.32
JAK1 P23458 1/20 0.32
PLK4 O00444 1/20 0.31
CHEK1 O14757 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869562 0.89 CHRNA7 (0.43) GSK3BDYRK1AWNT1CHRNA7KCNH2
SCHEMBL30869402 0.86 CHRNA7 (0.47) CHRNA7KCNH2TNIKPIK3C3PDE10A
SCHEMBL30869436 0.84 TNIK (0.36) CHRNA7KCNH2TNIKPIK3C3PDE10A
SCHEMBL30869702 0.83 CHRNA7 (0.42) GSK3BDYRK1AWNT1CHRNA7KCNH2
SCHEMBL30869522 0.83 CHRNA7 (0.42) GSK3BDYRK1AWNT1CHRNA7KCNH2
SCHEMBL30869618 0.83 BRAF (0.39) GSK3BDYRK1AWNT1TNIKBRAF
SCHEMBL30869780 0.83 CHRNA7 (0.41) GSK3BDYRK1AWNT1CHRNA7KCNH2
SCHEMBL30869718 0.83 CHRNA7 (0.41) GSK3BDYRK1AWNT1CHRNA7KCNH2
SCHEMBL30869764 0.82 CHRNA7 (0.42) GSK3BDYRK1AWNT1CHRNA7KCNH2
SCHEMBL30869612 0.81 CHRNA7 (0.40) GSK3BDYRK1AWNT1CHRNA7KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 EP disclosed
WO-2024054661-A2 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 GSK3B 3383/4885DYRK1A 2127/4885WNT1 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.